Home › Funds › Vestal Point Capital, LP › XENE
Vestal Point Capital, LP position in XENE
XENON PHARMACEUTICALS INC · Health Care
Vestal Point Capital, LP reported holding 700,000 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$42.3M, representing 0.99% of its reported portfolio and ranking #30 among its reported holdings. Vestal Point Capital, LP has disclosed XENE holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's XENE position evolved
Vestal Point Capital, LP first disclosed a stake in XENE in Q4 2023 at 175,000 shares (US$8.1M). The position peaked in Q2 2025 at 2,000,000 shares, worth US$62.6M. Across 11 filings, Vestal Point Capital, LP increased the stake 7 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 700,000 shares valued at US$42.3M — an increase of 60,100 shares quarter over quarter.. Notable position changes include a 129% increase in Q1 2024 (shares fell 9% over the following quarter), a 57% increase in Q3 2024 (shares were roughly flat over the following quarter), a 60% increase in Q1 2025 (shares fell 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 175.00K | $8.06M | New |
| Q1 2024 | 400.00K | $17.22M | Add |
| Q2 2024 | 525.00K | $20.47M | Add |
| Q3 2024 | 825.00K | $32.48M | Add |
| Q4 2024 | 810.00K | $31.75M | Reduce |
| Q1 2025 | 1.30M | $43.62M | Add |
| Q2 2025 | 2.00M | $62.60M | Add |
| Q3 2025 | 1.10M | $44.16M | Reduce |
| Q4 2025 | 600.00K | $26.89M | Reduce |
| Q1 2026 | 639.90K | $37.21M | Add |
| Q2 2026 | 700.00K | $42.25M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XENE and 13F data
XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 43 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XENE
- Avoro Capital Advisors LLC 5.78M sh · $348.75M · Q2 2026
- Polar Capital Holdings Plc 4.57M sh · $275.88M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 4.42M sh · $266.70M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.62M sh · $97.52M · Q2 2026
- Affinity Asset Advisors, LLC 1.59M sh · $96.27M · Q2 2026
- Siren, L.L.C. 1.32M sh · $79.59M · Q2 2026
- BRAIDWELL LP 1.13M sh · $68.29M · Q2 2026
- ORBIMED ADVISORS LLC 892.47K sh · $53.87M · Q2 2026
- Caligan Partners LP 889.94K sh · $53.72M · Q2 2026
- Caption Management, LLC 728.00K sh · $43.94M · Q2 2026
- Rock Springs Capital Management LP 683.91K sh · $41.28M · Q2 2026
- First Turn Management, LLC 600.20K sh · $36.23M · Q2 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held XENE?
Vestal Point Capital, LP has disclosed XENE holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is Vestal Point Capital, LP's current position in XENE?
As of Q2 2026, Vestal Point Capital, LP holds 700.00K shares of XENE (XENON PHARMACEUTICALS INC), valued at $42.25M, representing 0.99% of its reported portfolio and ranking #30.
Has Vestal Point Capital, LP been buying or selling XENE?
In the latest 13F filing (Q2 2026), Vestal Point Capital, LP increased its position in XENE. The position peaked in Q2 2025 at 2.00M shares.
Which other funds hold XENE?
Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.